한글목차

니티시논의 주요 성장 촉진요인

1. 시장 점유율 확대 및 신규 환자 수 증가

• 니티시논은 특히 유전성 티로신혈증 1형(HT-1)의 경우 전 세계에서 신생아 선별검사를 통한 조기 진단이 증가함에 따라 희귀대사질환 영역에서 점유율을 지속적으로 확대하고 있습니다.
• 소아 및 성인 환자에서 새로운 치료 시작이 증가하고 있는 것은 생존율 향상과 장기적인 질병 관리 개선에 힘입어 니티시논이 HT-1의 표준 치료제로 자리잡았기 때문입니다.
• 여러 브랜드 및 제네릭 의약품을 통한 접근성, 의사들의 높은 선호도, 전문 대사질환 치료센터에서의 지속적인 수요를 지원하고 있습니다.

2. 중요한 적응증으로 확대

• 유전성 티로신혈증 1형(HT-1) : 니티시논은 간기능 장애, 신장 기능 장애, 간세포암의 조기 발병을 예방하는 핵심 치료제로서의 지위를 유지하고 있습니다.
• 알캅토뇨증(AKU) : 호모겐티딘산 감소와 질병 진행 지연을 보여주는 데이터를 바탕으로 여러 지역에서 성인 환자 대상의 적응증 외 사용과 승인된 사용이 증가하고 있습니다.
• 신경인지 기능 보호: 신경학적 발달과 장기적인 결과를 유지하기 위해 조기 치료를 받은 소아 집단에서 사용이 증가하고 있습니다.
• 파이프라인 및 투여 최적화: 성인 대사성 질환 환자에서 장기 투여 전략과 실제 효능을 탐색하는 연구가 진행 중입니다.

3. 지역적 확장

• 니티시논은 북미, 유럽, 아시아, 중동에서 널리 사용되고 있으며, HT-1에 대한 전국적인 신생아 선별검사 프로그램을 시행하는 국가에서 높은 보급률을 보이고 있습니다.
• 유럽은 여전히 AKU 채택의 주요 지역이며, 아시아태평양은 대사성 질환 진단 및 전문 의료 인프라 확충으로 신흥 시장으로 부상하고 있습니다.
• 각 제약사들은 환자 접근성 향상을 위해 현지 생산 확대, 병원 공급체계 강화, 희귀질환 치료제의 급여 경로를 정비하는 등 다양한 노력을 기울이고 있습니다.

4. 신규 적응증 승인

• 유럽 및 기타 지역의 규제 당국은 알캅토뇨증에 대한 니티시논의 승인을 통해 HT-1을 넘어 임상적 적용 범위를 크게 확대했습니다.
• 현재 진행 중인 적응증 확대와 임상 가이드라인 개정으로 니티시논은 소아 및 성인 HT-1 1차 치료제로서의 입지를 더욱 공고히 하고 있습니다.
• 다른 티로신 대사장애 질환에 대한 지속적인 평가를 통해 향후 사용 범위가 더욱 확대될 수 있습니다.

5. HT-1과 AKU의 강력한 물량 추이

• HT-1은 평생 치료와 환자 생존율의 향상으로 치료 건수가 강세를 보이고 있으며, 치료의 주요 촉진요인으로 작용하고 있습니다.
• 알캅토뇨증(AKU)의 경우, 유럽을 중심으로 한 진단율 향상과 전문의 진료 의뢰 증가가 꾸준한 처방 증가를 촉진하고 있습니다.
• 리얼월드 증거는 장기적인 생화학적 조절과 질병 합병증 감소를 입증하여 임상의의 신뢰도를 높이고 있습니다.

6. 경쟁 차별화 및 시장 동향

• 티로신 대사 장애에서 독성 대사산물 축적의 근본 원인을 해결하는 최초의 효소 억제제입니다.
• 경구 투여를 통한 만성 치료 모델은 간이식이나 지지요법만 사용하는 것에 비해 사용 편의성을 제공합니다.
• 신생아 유전자 검사, 조기 개입, 희귀질환에 초점을 맞춘 의료 정책의 광범위한 동향이 시장에 도움이 되고 있습니다.
• 리얼월드 레지스트리와 장기 추적 데이터의 활용이 확대되면서 보험사와 의사의 신뢰가 강화되고 있습니다.

최근 니티시논에 관한 발전

• 니티시논 시장은 알캅토뇨증 적응증 확대, HT-1의 장기적인 실제 임상 결과, 제네릭 의약품 및 국가 환급 프로그램을 통한 접근성 향상에 초점을 맞추었습니다. 유럽 대사질환 네트워크는 지속적인 질병 통제와 생존율 향상을 확인하는 리얼월드 레지스트리 데이터를 지속적으로 공개하고 있습니다. 여러 제조업체가 공급 확대 및 처방 개선(소아 투여 포함)을 발표했으며, 이러한 발전으로 니티시논은 티로신 대사 경로 장애에 대한 표준 대사 치료제로서의 입지를 더욱 공고히 하고 있습니다.

니티시논의 주요 7개국(미국, 독일, 프랑스, 이탈리아, 스페인, 스페인, 영국, 일본) 시장을 조사 분석했으며, 각국 시장 규모와 예측, 연구개발(R&D) 활동, 경쟁 구도 등의 정보를 전해드립니다.

목차

제1장 리포트의 개요

제2장 선천성 대사이상증 및 티로신혈증 I형 등의 승인된 적응증에서 니티시논의 개요

제3장 니티시논의 경쟁 상황(출시의 치료법)

제4장 경쟁 구도(후기 단계의 새로운 니티시논 요법)

제5장 니티시논 시장 평가

제6장 니티시논 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 소개

제12장 리포트 구입 옵션

영문목차

Key Factors Driving Nitisinone Growth

1. Market Share Gains and New Patient Starts

• Nitisinone continues to gain share in the rare metabolic disease space, particularly in hereditary tyrosinemia type 1 (HT-1), as early diagnosis through newborn screening increases globally.
• Rising pediatric and adult patient starts are being driven by improved survival and long-term disease control, making Nitisinone the standard of care in HT-1.
• Commercial availability through multiple branded and generic versions, along with strong physician familiarity, is supporting sustained demand across specialty metabolic centers.

2. Expansion Across Key Indications

• Hereditary Tyrosinemia Type 1 (HT-1): Nitisinone remains the cornerstone therapy, preventing liver failure, renal dysfunction, and hepatocellular carcinoma when started early.
• Alkaptonuria (AKU): Increasing off-label and approved use in several regions for adult patients, supported by data showing reductions in homogentisic acid and slowed disease progression.
• Neurocognitive Protection: Growing use in early-treated pediatric populations to preserve neurological development and long-term outcomes.
• Pipeline and Dosing Optimization: Ongoing studies are exploring long-term dosing strategies and real-world effectiveness in adult metabolic disease populations.

3. Geographic Expansion

• Nitisinone is widely available across North America, Europe, Asia, and the Middle East, with strong uptake in countries that have national newborn screening programs for HT-1.
• Europe remains a leading region for AKU adoption, while Asia-Pacific is emerging due to expanded metabolic disease diagnostics and specialty care infrastructure.
• Manufacturers are expanding local manufacturing, hospital access, and rare-disease reimbursement pathways to improve patient reach.

4. New Indication Approvals

• Regulatory agencies in Europe and other regions have approved nitisinone for alkaptonuria, significantly broadening its clinical footprint beyond HT-1.
• Ongoing label updates and clinical guideline revisions continue to reinforce nitisinone as first-line therapy in HT-1 across pediatric and adult populations.
• Continued evaluation in additional tyrosine metabolism disorders could further expand future use.

5. Strong HT-1 and AKU Volume Momentum

• HT-1 remains the primary growth driver, with strong treatment volumes due to lifelong therapy and improved patient survival.
• In AKU, increasing diagnosis rates and specialty referrals are driving steady prescription growth, particularly in Europe.
• Real-world evidence supports long-term biochemical control and reduced disease complications, strengthening clinician confidence.

6. Competitive Differentiation and Market Trends

• First-in-class enzyme inhibitor that addresses the root cause of toxic metabolite accumulation in tyrosine metabolism disorders.
• Oral, chronic therapy model offers ease of use compared to liver transplantation or supportive care alone.
• The market benefits from broader trends toward newborn genetic screening, early intervention, and rare-disease-focused healthcare policies.
• Growing reliance on real-world registries and long-term follow-up data is reinforcing payer and physician trust.

Nitisinone Recent Developments

• The Nitisinone market have focused on expanded use in alkaptonuria, long-term real-world outcomes in HT-1, and improved access through generics and national reimbursement programs. European metabolic disease networks continue to publish real-world registry data confirming sustained disease control and improved survival. Several manufacturers have also announced supply expansions and formulation improvements, including pediatric-friendly dosing. These developments continue to reinforce Nitisinone's position as the gold standard metabolic therapy for tyrosine pathway disorders.

"Nitisinone Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of Nitisinone for approved indication like Inborn error metabolic disorders and Tyrosinaemia type I in the 7MM. A detailed picture of Nitisinone's existing usage in anticipated entry and performance in approved indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the Nitisinone for approved indications. The Nitisinone market report provides insights about Nitisinone's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Nitisinone performance, future market assessments inclusive of the Nitisinone market forecast analysis for approved indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Nitisinone sales forecasts, along with factors driving its market.

Nitisinone Drug Summary

Nitisinone (Orfadin) is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase (HPPD), used as an adjunct to dietary restriction of tyrosine and phenylalanine for treating hereditary tyrosinemia type 1 (HT-1) in patients of all ages and for reducing urinary homogentisic acid (HGA) in adults with alkaptonuria (AKU). By competitively blocking HPPD early in the tyrosine catabolic pathway, it prevents the accumulation of toxic metabolites such as fumarylacetoacetate and maleylacetoacetate (which form succinylacetone, causing liver, kidney, and neurological damage in HT-1) downstream of the deficient fumarylacetoacetate hydrolase (FAH) enzyme, thereby halting disease progression and often eliminating the need for liver transplantation. Administered orally as capsules or oral suspension with dose adjustments based on body weight and plasma tyrosine monitoring to avoid corneal and keratopathy risks from tyrosine elevation, Nitisinone has transformed HT-1 management since its introduction. The report provides Nitisinone's sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the Nitisinone Market Report

The report provides insights into:

• A comprehensive product overview including the Nitisinone MoA, description, dosage and administration, research and development activities in approved indication like Inborn error metabolic disorders and Tyrosinaemia type I.
• Elaborated details on Nitisinone regulatory milestones and other development activities have been provided in Nitisinone market report.
• The report also highlights Nitisinone's cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved indications across the United States, Europe, and Japan.
• The Nitisinone market report also covers the patents information, generic entry and impact on cost cut.
• The Nitisinone market report contains current and forecasted Nitisinone sales for approved indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Nitisinone market report also features the SWOT analysis with analyst views for Nitisinone in approved indications.

Methodology:

The Nitisinone market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Nitisinone Analytical Perspective by DelveInsight

• In-depth Nitisinone Market Assessment

This Nitisinone sales market forecast report provides a detailed market assessment of Nitisinone for approved indication like Inborn error metabolic disorders and Tyrosinaemia type I in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Nitisinone sales data uptil 2034.

• Nitisinone Clinical Assessment

The Nitisinone market report provides the clinical trials information of Nitisinone for approved indications covering trial interventions, trial conditions, trial status, start and completion dates.

Nitisinone Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Nitisinone Market Potential & Revenue Forecast

• Projected market size for the Nitisinone and its key indications
• Estimated Nitisinone sales potential (Nitisinone peak sales forecasts)
• Nitisinone Pricing strategies and reimbursement landscape

Nitisinone Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Nitisinone Market positioning compared to existing treatments
• Nitisinone Strengths & weaknesses relative to competitors

Nitisinone Regulatory & Commercial Milestones

• Nitisinone Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Nitisinone Clinical Differentiation

• Nitisinone Efficacy & safety advantages over existing drugs
• Nitisinone Unique selling points

Nitisinone Market Report Highlights

• In the coming years, the Nitisinone market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Nitisinone companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Nitisinone's dominance.
• Other emerging products for Inborn error metabolic disorders and Tyrosinaemia type I are expected to give tough market competition to Nitisinone and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Nitisinone in approved indications.
• Analyse Nitisinone cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Nitisinone sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Nitisinone in approved indications.

Key Questions:

• What is the class of therapy, route of administration and mechanism of action of Nitisinone? How strong is Nitisinone's clinical and commercial performance?
• What is Nitisinone's clinical trial status in each individual indications such as Inborn error metabolic disorders and Tyrosinaemia type I and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Nitisinone Manufacturers?
• What are the key designations that have been granted to Nitisinone for approved indications? How are they going to impact Nitisinone's penetration in various geographies?
• What is the current and forecasted Nitisinone market scenario for approved indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Nitisinone in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Nitisinone for approved indications?
• Which are the late-stage emerging therapies under development for the treatment of approved indications?
• How cost-effective is Nitisinone? What is the duration of therapy and what are the geographical variations in cost per patient?

Table of Contents

1. Report Introduction

2. Nitisinone Overview in approved indications like Inborn error metabolic disorders and Tyrosinaemia type I

• 2.1. Product Detail
• 2.2. Nitisinone Clinical Development
  • 2.2.1. Nitisinone Clinical studies
  • 2.2.2. Nitisinone Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Nitisinone Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Nitisinone Therapies)

5. Nitisinone Market Assessment

• 5.1. Nitisinone Market Outlook in approved indications
• 5.2. 7MM Analysis
  • 5.2.1. Nitisinone Market Size in the 7MM for approved indications
• 5.3. Country-wise Market Analysis
  • 5.3.1. Nitisinone Market Size in the United States for approved indications
  • 5.3.2. Nitisinone Market Size in Germany for approved indications
  • 5.3.3. Nitisinone Market Size in France for approved indications
  • 5.3.4. Nitisinone Market Size in Italy for approved indications
  • 5.3.5. Nitisinone Market Size in Spain for approved indications
  • 5.3.6. Nitisinone Market Size in the United Kingdom for approved indications
  • 5.3.7. Nitisinone Market Size in Japan for approved indications

6. Nitisinone SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options